The choice of detecting Down syndrome: does money matter?

Area of Science:

• Medical Economics
• Prenatal Diagnostics
• Public Health Policy

Background:

• Prenatal diagnosis for Down syndrome via amniocentesis involves weighing risks of an affected child against miscarriage of an unaffected fetus.
• Parental decisions are influenced by complex ethical considerations and the financial implications of diagnostic procedures.
• The French healthcare system provides a unique setting to study the impact of varying reimbursement schemes on amniocentesis uptake.

Purpose of the Study:

• To investigate how variations in the monetary costs of amniocentesis, influenced by French Health insurance, affect parental decisions.
• To assess the impact of being labeled 'high-risk' versus full reimbursement on the probability of undergoing amniocentesis.
• To examine potential adverse outcomes associated with amniocentesis, such as premature birth and low birth weight.

Main Methods:

• Analysis of parental decision-making regarding amniocentesis within the French healthcare system.
• Comparison of amniocentesis uptake rates across different reimbursement schemes.
• Review of existing data on post-amniocentesis pregnancy outcomes.

Main Results:

• Eligibility for full reimbursement of amniocentesis costs significantly increases the likelihood of parents opting for the test.
• The 'high-risk' designation by the health system has a comparatively modest effect on parental choices.
• Evidence suggests amniocentesis is associated with an increased risk of premature birth and low birth weight.

Conclusions:

• Financial incentives, specifically full insurance coverage, play a substantial role in parental decisions for prenatal diagnosis.
• Healthcare system policies on reimbursement can effectively influence the utilization of diagnostic procedures like amniocentesis.
• Amniocentesis may carry risks of adverse birth outcomes, necessitating careful consideration beyond genetic diagnosis.